ABCL – AbCellera Biologics Inc.
Name : AbCellera Biologics Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $0.0000
EPSttm :
[iframe https://s.tradingview.com/embed-widget/symbol-info/?locale=in&symbol=ABCL
#%7B%22symbol%22%3A%22A%22%2C%22width%22%3A%22100%25%22%2C%22colorTheme%22%3A%22light%22%2C%22isTransparent%22%3Atrue%2C%22height%22%3A203%2C%22utm_source%22%3A%22themarketstracker.com%22%2C%22utm_medium%22%3A%22widget_new%22%2C%22utm_campaign%22%3A%22symbol-info%22%7D 900 250 ]
[iframe https://api.stockdio.com/visualization/financial/charts/v1/PricesChange?app-key=F086EEE750E14D8D8A456DB88B2D6D8C&symbol=ABCL
&conditionalVolume=false&allowPeriodChange=false&tooltipsStyle=None&palette=Financial-Light&showBorderAndTitle=false 300 200 ]
Float Short %
19.68
Margin Of Safety %
Put/Call OI Ratio
0.15
EPS Next Q Diff
-0.04
EPS Last/This Y
-0.05
EPS This/Next Y
0.1
Price
5.76
Target Price
9.33
Analyst Recom
1.25
Performance Q
36.73
Relative Volume
1
Beta
0.68
Ticker: ABCL
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | ABCL | 4.18 | 0.28 | 0.28 | 81958 |
| 2025-09-09 | ABCL | 4.24 | 0.28 | 0.17 | 82088 |
| 2025-09-10 | ABCL | 4.28 | 0.28 | 0.08 | 82281 |
| 2025-09-11 | ABCL | 4.62 | 0.26 | 0.11 | 85662 |
| 2025-09-12 | ABCL | 4.47 | 0.26 | 0.66 | 86431 |
| 2025-09-15 | ABCL | 4.36 | 0.27 | 0.32 | 87287 |
| 2025-09-16 | ABCL | 4.77 | 0.27 | 0.06 | 87287 |
| 2025-09-17 | ABCL | 4.57 | 0.26685102460469 | 0.14828544949027 | 89332 |
| 2025-09-18 | ABCL | 4.71 | 0.27 | 0.09 | 91489 |
| 2025-09-19 | ABCL | 4.5 | 0.27 | 0.16 | 90456 |
| 2025-09-22 | ABCL | 4.82 | 0.15 | 0.10 | 75302 |
| 2025-09-23 | ABCL | 4.9 | 0.14 | 0.03 | 79265 |
| 2025-09-24 | ABCL | 4.76 | 0.14 | 0.13 | 83386 |
| 2025-09-25 | ABCL | 4.64 | 0.14 | 0.09 | 84443 |
| 2025-09-26 | ABCL | 4.75 | 0.14 | 0.03 | 84873 |
| 2025-09-29 | ABCL | 4.86 | 0.14 | 0.10 | 85923 |
| 2025-09-30 | ABCL | 5.02 | 0.14 | 0.08 | 86334 |
| 2025-10-01 | ABCL | 6 | 0.14 | 0.08 | 86237 |
| 2025-10-02 | ABCL | 5.97 | 0.14 | 0.14 | 90848 |
| 2025-10-03 | ABCL | 5.89 | 0.15 | 0.11 | 100439 |
| 2025-10-06 | ABCL | 5.84 | 0.15 | 0.07 | 101948 |
| 2025-10-07 | ABCL | 5.76 | 0.15 | 0.11 | 104304 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | ABCL | 4.17 | 4.7 | - | -0.59 |
| 2025-09-09 | ABCL | 4.23 | 4.7 | - | -0.59 |
| 2025-09-10 | ABCL | 4.28 | 4.7 | - | -0.59 |
| 2025-09-11 | ABCL | 4.61 | 4.7 | - | -0.59 |
| 2025-09-12 | ABCL | 4.46 | 4.7 | - | -0.59 |
| 2025-09-15 | ABCL | 4.34 | 4.7 | - | -0.59 |
| 2025-09-16 | ABCL | 4.77 | 4.7 | - | -0.59 |
| 2025-09-17 | ABCL | 4.56 | 4.7 | - | -0.59 |
| 2025-09-18 | ABCL | 4.71 | 4.7 | - | -0.59 |
| 2025-09-19 | ABCL | 4.50 | 4.7 | - | -0.59 |
| 2025-09-22 | ABCL | 4.83 | 4.7 | - | -0.60 |
| 2025-09-23 | ABCL | 4.89 | 4.7 | - | -0.60 |
| 2025-09-24 | ABCL | 4.77 | 4.7 | - | -0.60 |
| 2025-09-25 | ABCL | 4.65 | 4.7 | - | -0.60 |
| 2025-09-26 | ABCL | 4.74 | 4.7 | - | -0.60 |
| 2025-09-29 | ABCL | 4.87 | 4.7 | - | -0.60 |
| 2025-09-30 | ABCL | 5.02 | 4.7 | - | -0.60 |
| 2025-10-01 | ABCL | 5.97 | 4.7 | - | -0.60 |
| 2025-10-02 | ABCL | 5.97 | 4.7 | - | -0.60 |
| 2025-10-03 | ABCL | 5.89 | 4.7 | - | -0.60 |
| 2025-10-06 | ABCL | 5.87 | 4.7 | - | -0.60 |
| 2025-10-07 | ABCL | 5.76 | 4.7 | - | -0.60 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | ABCL | 0.00 | -17.43 | 18.54 |
| 2025-09-09 | ABCL | 0.00 | -17.43 | 18.54 |
| 2025-09-10 | ABCL | 0.00 | -17.43 | 18.54 |
| 2025-09-11 | ABCL | 0.00 | -17.43 | 19.18 |
| 2025-09-12 | ABCL | 0.00 | -17.43 | 19.18 |
| 2025-09-15 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-16 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-17 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-18 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-19 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-22 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-23 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-24 | ABCL | 0.00 | -17.39 | 19.18 |
| 2025-09-25 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-09-26 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-09-29 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-09-30 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-10-01 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-10-02 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-10-03 | ABCL | 0.00 | -17.39 | 19.68 |
| 2025-10-06 | ABCL | 0.00 | -9.97 | 19.68 |
| 2025-10-07 | ABCL | 0.00 | -9.97 | 19.68 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
[iframe https://widget.finnhub.io/widgets/historical-eps?symbol=ABCL
589 360 ]
Last Quarter Act. EPS
-0.12
Avg. EPS Est. Current Quarter
-0.16
Avg. EPS Est. Next Quarter
-0.16
Insider Transactions
Institutional Transactions
-9.97
Beta
0.68
Average Sales Estimate Current Quarter
6
Average Sales Estimate Next Quarter
6
Fair Value
Quality Score
21
Growth Score
29
Sentiment Score
84
Actual DrawDown %
92
Max Drawdown 5-Year %
Target Price
9.33
P/E
Forward P/E
PEG
P/S
52.44
P/B
1.71
P/Free Cash Flow
EPS
-0.56
Average EPS Est. Cur. Y
-0.6
EPS Next Y. (Est.)
-0.5
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-503.91
Relative Volume
1
Return on Equity vs Sector %
-41.6
Return on Equity vs Industry %
-27.9
EPS 1 7Days Diff
EPS 1 30Days Diff
0.06
EBIT Estimation
[iframe https://widget.finnhub.io/widgets/recommendation?symbol=ABCL
589 450 ]
[iframe https://widget.finnhub.io/widgets/eps-estimate?symbol=ABCL
589 450 ]
AbCellera Biologics Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 596
AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its product pipeline includes ABCL635, an antibody-drug candidate, which is in preclinical trial to treat metabolic and endocrine conditions; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in preclinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; and partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.
stock quote shares ABCL – AbCellera Biologics Inc. Stock Price stock today
news today ABCL – AbCellera Biologics Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ABCL – AbCellera Biologics Inc. yahoo finance google finance
stock history ABCL – AbCellera Biologics Inc. invest stock market
stock prices ABCL
premarket after hours
ticker ABCL
fair value insiders trading